🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing around the world, with estimates suggesting more than 82 million infections per year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the context of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring showed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

One new antibiotic, also known as Nuzolvence, was authorized by the US FDA in mid-December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists anticipate that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in the same week. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This authorization represents a major breakthrough in the management of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Results and Worldwide Availability

According to findings detailed in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which uses two antibiotics. The trial involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have expressed positive views. Access to a single-dose, oral treatment of this kind is seen as a "critical tool" for gonorrhoea control. This is viewed as crucial to lessen the impact of the illness for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.